PMID- 33118081
OWN - NLM
STAT- MEDLINE
DCOM- 20210906
LR  - 20220426
IS  - 1615-6692 (Electronic)
IS  - 0340-9937 (Linking)
VI  - 46
IP  - Suppl 2
DP  - 2021 Sep
TI  - Value of microalbuminuria in the diagnosis of heart failure with preserved 
      ejection fraction.
PG  - 215-221
LID - 10.1007/s00059-020-04985-1 [doi]
AB  - OBJECTIVE: Elevated microalbuminuria (MAU) levels have been demonstrated in 
      patients with heart failure with reduced ejection fraction (HFrEF). However, 
      nothing is known about MAU levels in patients with heart failure with preserved 
      ejection fraction (HFpEF). Therefore, the aim of our study was to explore the 
      relationship between MAU levels and HFpEF. METHODS: The MAU and N‑terminal B‑type 
      natriuretic peptide (NT-proBNP) concentrations were examined in 260 participants, 
      including 160 patients with HFpEF and 100 control subjects without HF. 
      Echocardiography was performed on all study participants. The patients with HFpEF 
      were divided into class II, III, or IV according to the New York Heart 
      Association (NYHA) classification. RESULTS: The MAU levels in the HFpEF group 
      were significantly higher than those in the non-HF group (58.97 +/- 89.84 vs. 
      19.56 +/- 29.34, p > 0.05). However, there was no significant difference in the 
      levels of MAU among NYHA class II-IV patients in the HFpEF group (p > 0.05). In 
      Pearson linear correlation analysis, MAU levels in the HFpEF group were 
      positively correlated with left atrial diameter (LAD; r = 0.344, p < 0.05), but 
      negatively correlated with hemoglobin (r = - 0.233, p < 0.05). The area under the 
      ROC curve (AUC) of MAU for the diagnosis of HFpEF was 0.83 (95% CI [0.76, 0.90], 
      p < 0.05), the sensitivity was 72.50%, and the specificity was 82.0%. The AUC of 
      NT-proBNP was 0.88 (95% CI [0.83, 0.94], p < 0.05), the sensitivity was 82%, and 
      the specificity was 73.8%. The AUC of MAU combined with NT-proBNP was 0.91 
      (95% CI [0.86, 0.96], p < 0.05). CONCLUSION: Our results show that MAU can be 
      used as a biomarker for the diagnosis of HFpEF. Combined detection of MAU with 
      NT-proBNP has clinical value in improving the accuracy of diagnosis of HFpEF. 
      However, there is no significant correlation between MAU levels and the severity 
      of HFpEF.
CI  - (c) 2020. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
FAU - Chen, Liuying
AU  - Chen L
AD  - Zhejiang Chinese Medical University, Hangzhou, China.
AD  - Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang 
      University School of Medicine, Hangzhou, China.
FAU - Jin, Chaolun
AU  - Jin C
AD  - Nanjing Medical University, Nanjing, China.
AD  - Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang 
      University School of Medicine, Hangzhou, China.
FAU - Chen, Lijun
AU  - Chen L
AD  - Zhejiang Chinese Medical University, Hangzhou, China.
AD  - Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang 
      University School of Medicine, Hangzhou, China.
FAU - Li, Miaofu
AU  - Li M
AD  - Nanjing Medical University, Nanjing, China.
AD  - Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang 
      University School of Medicine, Hangzhou, China.
FAU - Zhong, Yigang
AU  - Zhong Y
AD  - Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang 
      University School of Medicine, Hangzhou, China. zhongyigangly@163.com.
FAU - Xu, Yizhou
AU  - Xu Y
AD  - Nanjing Medical University, Nanjing, China. qqyzxu@hotmail.com.
AD  - Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang 
      University School of Medicine, Hangzhou, China. qqyzxu@hotmail.com.
LA  - eng
PT  - Journal Article
TT  - Stellenwert der Mikroalbuminurie bei der Diagnose einer Herzinsuffizienz mit 
      erhaltener Ejektionsfraktion.
DEP - 20201028
PL  - Germany
TA  - Herz
JT  - Herz
JID - 7801231
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Biomarkers
MH  - *Heart Failure/diagnosis
MH  - Humans
MH  - Natriuretic Peptide, Brain
MH  - Peptide Fragments
MH  - Prognosis
MH  - Stroke Volume
MH  - *Ventricular Dysfunction, Left
OTO - NOTNLM
OT  - Biomarkers
OT  - Cardiac failure
OT  - Echocardiography
OT  - NT-proBNP
OT  - Peptide fragments
EDAT- 2020/10/30 06:00
MHDA- 2021/09/07 06:00
CRDT- 2020/10/29 05:55
PHST- 2020/03/19 00:00 [received]
PHST- 2020/09/04 00:00 [accepted]
PHST- 2020/07/30 00:00 [revised]
PHST- 2020/10/30 06:00 [pubmed]
PHST- 2021/09/07 06:00 [medline]
PHST- 2020/10/29 05:55 [entrez]
AID - 10.1007/s00059-020-04985-1 [pii]
AID - 10.1007/s00059-020-04985-1 [doi]
PST - ppublish
SO  - Herz. 2021 Sep;46(Suppl 2):215-221. doi: 10.1007/s00059-020-04985-1. Epub 2020 
      Oct 28.